Vistagen Therapeutics Inc (VTGN)

03:10 AM

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World

03:10 AM

Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa

Jun 03, 2025

Jun 03, 2025

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World

Jun 03, 2025

Jun 03, 2025

Vistagen expects phase 3 trial results by 2026 - Investing.com India

Jun 03, 2025

Jun 02, 2025

VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN St - GuruFocus

Jun 02, 2025

Jun 02, 2025

Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - marketscreener.com

Jun 02, 2025

Jun 02, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year - Yahoo Finance

Jun 02, 2025

May 31, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat

May 31, 2025

May 28, 2025

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise

May 28, 2025

May 28, 2025

Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025

May 23, 2025

Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan

May 23, 2025

May 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat

May 11, 2025

May 08, 2025

254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat

May 08, 2025

May 06, 2025

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

May 06, 2025

May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025

May 04, 2025

Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

May 04, 2025

Apr 29, 2025

JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Apr 29, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 24, 2025

JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Apr 24, 2025

Apr 17, 2025

Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan

Apr 17, 2025

Apr 17, 2025

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace

Apr 17, 2025

Apr 08, 2025

Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World

Apr 08, 2025

Apr 06, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World

Apr 06, 2025

Apr 04, 2025

VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK

Apr 04, 2025

Apr 03, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Apr 03, 2025

Apr 03, 2025

Mental Disorder Treatment Market Set to Witness Significant - openPR.com

Apr 03, 2025

Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025

Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com

Mar 21, 2025

Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025

Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025

Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025

Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025

Mar 12, 2025

Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com

Mar 12, 2025

Mar 08, 2025

VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire

Mar 08, 2025

Mar 04, 2025

Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire

Mar 04, 2025

Mar 02, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN

Mar 02, 2025

Feb 27, 2025

VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com

Feb 27, 2025

Feb 27, 2025

VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire

Feb 27, 2025

Feb 25, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat

Feb 25, 2025

Feb 20, 2025

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan

Feb 20, 2025

Feb 19, 2025

VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire

Feb 19, 2025

Feb 18, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Feb 18, 2025